{"id":"etoricoxib-arcoxia","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Edema"},{"rate":null,"effect":"Dyspepsia"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Cardiovascular events (myocardial infarction, stroke)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a selective COX-2 inhibitor, etoricoxib blocks the COX-2 enzyme preferentially over COX-1, thereby decreasing prostaglandin synthesis in inflamed tissues. This results in anti-inflammatory and analgesic effects with a potentially improved gastrointestinal safety profile compared to non-selective NSAIDs, though cardiovascular risks remain a consideration.","oneSentence":"Etoricoxib selectively inhibits cyclooxygenase-2 (COX-2), reducing the production of prostaglandins that mediate inflammation and pain.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:29:50.653Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Osteoarthritis"},{"name":"Ankylosing spondylitis"},{"name":"Acute pain"},{"name":"Chronic pain conditions"}]},"trialDetails":[{"nctId":"NCT07454369","phase":"PHASE1","title":"Comparative Bioavailability Study Between Etoricoxib / Betamethasone Administered Individually or in Combination","status":"COMPLETED","sponsor":"Laboratorios Silanes S.A. de C.V.","startDate":"2022-10-24","conditions":"Healthy","enrollment":42},{"nctId":"NCT05014490","phase":"PHASE1","title":"Bioequivalence Study of Test and Reference 120 mg Etoricoxib Film-coated Tablets in Healthy Volunteers","status":"COMPLETED","sponsor":"Darnitsa Pharmaceutical Company","startDate":"2021-02-24","conditions":"Bioequivalence, Healthy Subjects","enrollment":28},{"nctId":"NCT01294696","phase":"","title":"Survey of Osteoarthritis Real World Therapies (MK-0663-140)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2010-10","conditions":"Osteoarthritis","enrollment":1261},{"nctId":"NCT00092729","phase":"PHASE3","title":"An Investigational Drug Study in the Treatment of Primary Dysmenorrhea (0663-064)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2002-06-07","conditions":"Dysmenorrhea","enrollment":129},{"nctId":"NCT00140972","phase":"PHASE4","title":"A Study to Assess Etoricoxib Versus Diclofenac in Chinese Patients With Osteoarthritis of the Knee or Hip (0663-080)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-12-03","conditions":"Osteoarthritis","enrollment":160},{"nctId":"NCT00092703","phase":"PHASE3","title":"Investigational Drug Versus an Approved Drug in Patients With Osteoarthritis (0663-061)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2002-06-27","conditions":"Osteoarthritis","enrollment":6000},{"nctId":"NCT00380627","phase":"PHASE4","title":"Quality of Life With Arcoxia in Women With Dysmenorrhea (0663-094)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-09-01","conditions":"Pain","enrollment":337},{"nctId":"NCT00269191","phase":"PHASE3","title":"A Study to Assess the Safety and Efficacy of an Investigational Drug in Patients With Osteoarthritis (0663-071)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-02-05","conditions":"Osteoarthritis","enrollment":528},{"nctId":"NCT00142558","phase":"PHASE4","title":"A Study Evaluating the Effect of Etoricoxib and Indomethacin in the Treatment of Acute Gout (0663-081)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-01-01","conditions":"Acute Gout","enrollment":180},{"nctId":"NCT00092768","phase":"PHASE3","title":"A Study of MK0663 and an Approved Drug in the Treatment of Osteoarthritis (0663-076)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-03-01","conditions":"Osteoarthritis","enrollment":500},{"nctId":"NCT00542087","phase":"PHASE3","title":"Etoricoxib vs. Diclofenac in OA (0663-805)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2002-03-22","conditions":"Osteoarthritis","enrollment":516},{"nctId":"NCT00092755","phase":"PHASE3","title":"An Investigational Drug in Patients With Osteoarthritis (0663-073)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-04-09","conditions":"Osteoarthritis","enrollment":548},{"nctId":"NCT00092781","phase":"PHASE3","title":"A Study of MK0663 and an Approved Drug in the Treatment of Osteoarthritis (0663-077)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-03-01","conditions":"Osteoarthritis","enrollment":500},{"nctId":"NCT01980940","phase":"PHASE1, PHASE2","title":"The Single Dose Pharmacokinetics of Two and Proof of Efficacy of One New Etoricoxib Gel Formulation in Participants With Osteoarthritis (MK-0663-168)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2013-12-23","conditions":"Osteoarthritis Pain","enrollment":70},{"nctId":"NCT01208207","phase":"PHASE3","title":"A Two-Part 26-Week Study of Etoricoxib as Treatment for Ankylosing Spondylitis (AS) (MK-0663-108)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2010-09-27","conditions":"Spondylitis, Ankylosing","enrollment":1015},{"nctId":"NCT01208181","phase":"PHASE3","title":"A Two-Part, 12-Week Study of Etoricoxib as a Treatment for Rheumatoid Arthritis (RA) (MK-0663-107)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2010-09-27","conditions":"Arthritis, Rheumatoid","enrollment":1404},{"nctId":"NCT01327638","phase":"","title":"Safety of Etoricoxib (MK-0663) in Patients With Spondyloarthropathy (SpA)/Ankylosing Spondylitis (AS) in Sweden (EP07013.013.11.082)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2011-02-15","conditions":"Spondylarthropathies; Spondylitis, Ankylosing","enrollment":21108},{"nctId":"NCT05256342","phase":"NA","title":"Biomarkers for Prediction of Analgesic Efficacy in Knee OA.","status":"COMPLETED","sponsor":"Rambam Health Care Campus","startDate":"2021-12-30","conditions":"Knee, Osteoarthritis (OA), Biomarkers for Prediction of OA Treatment Efficacy","enrollment":17},{"nctId":"NCT05683574","phase":"PHASE3","title":"Fixed-dose Combination of Etoricoxib + Cyclobenzaprine for Pain Relief After Third Molar Extraction in Brazil","status":"WITHDRAWN","sponsor":"Eurofarma Laboratorios S.A.","startDate":"2026-05-30","conditions":"Third Molar Extraction","enrollment":""},{"nctId":"NCT04920019","phase":"NA","title":"Opioid Sparing Effect of Thoracic Epidural Analgesia for Open Upper Abdominal Surgery","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2020-10-22","conditions":"Hepatoma, Pancreas Cancer","enrollment":140},{"nctId":"NCT05533073","phase":"PHASE1","title":"Comparative Bioavailability Study Between Etoricoxib and Tramadol, Administered Individually or in Combination","status":"COMPLETED","sponsor":"Laboratorios Silanes S.A. de C.V.","startDate":"2020-08-03","conditions":"Healthy","enrollment":42},{"nctId":"NCT05532280","phase":"PHASE1","title":"Bioequivalence Study of Etoricoxib in Healthy Adult Subjects Under Fasting Condition","status":"COMPLETED","sponsor":"Future University in Egypt","startDate":"2020-12-28","conditions":"Healthy Subjects","enrollment":30},{"nctId":"NCT02503839","phase":"PHASE1","title":"Therapeutic Vaccination and Immune Modulation - New Treatment Strategies for the MDR Tuberculosis Pandemic","status":"COMPLETED","sponsor":"Anne Margarita Dyrhol Riise","startDate":"2015-11","conditions":"Tuberculosis","enrollment":39},{"nctId":"NCT00393354","phase":"PHASE3","title":"Effect of Etoricoxib to Treat Chronic Low Back Pain (0663-041)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2000-04","conditions":"Recurrent Low Back Pain","enrollment":325},{"nctId":"NCT00242489","phase":"PHASE2","title":"Etoricoxib in the Treatment of Osteoarthritis (MK-0663-007)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"1998-06","conditions":"Osteoarthritis","enrollment":1167},{"nctId":"NCT00250445","phase":"PHASE3","title":"A Study to Evaluate the Safety of an Investigational Drug (Etoricoxib) in Patients With Osteoarthritis (OA) or Rheumatoid Arthritis (RA)(0663-066)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-01","conditions":"Rheumatoid Arthritis,Osteoarthritis","enrollment":23498},{"nctId":"NCT00393211","phase":"PHASE3","title":"Effect of Etoricoxib to Treat Chronic Low Back Pain (0663-042)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2000-04","conditions":"Recurrent Low Back Pain","enrollment":319},{"nctId":"NCT01685424","phase":"","title":"Etoricoxib Prescribing Patterns and Adverse Events of Interest in Primary Care in the United Kingdom (MK-0663-162 AM1)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-06-30","conditions":"Osteoarthritis, Rheumatoid Arthritis, Ankylosing Spondylitis","enrollment":79189},{"nctId":"NCT01077843","phase":"","title":"Post-authorization Safety Study of Etoricoxib and Other Anti-inflammatory Therapies in European Patients With Ankylosing Spondylitis (MK-0663-163)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2009-08-17","conditions":"Ankylosing Spondylitis","enrollment":27381},{"nctId":"NCT01429168","phase":"PHASE4","title":"A Study of Etoricoxib in Participants With Osteoarthritis Not Responding to Analgesic Drugs (MK-0663-142)","status":"WITHDRAWN","sponsor":"Organon and Co","startDate":"2011-10","conditions":"Osteoarthritis","enrollment":""},{"nctId":"NCT00092742","phase":"PHASE3","title":"Investigational Drug Versus an Approved Drug in Patients With Rheumatoid Arthritis (0663-072)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-02","conditions":"Rheumatoid Arthritis","enrollment":4086},{"nctId":"NCT00095017","phase":"PHASE2","title":"Safety and Efficacy of an Investigational Drug Versus Placebo in the Treatment of Cancer Pain (0663-083)","status":"WITHDRAWN","sponsor":"Organon and Co","startDate":"2004-11","conditions":"Bone Neoplasms","enrollment":""},{"nctId":"NCT00380523","phase":"PHASE4","title":"Analgesic Treatment Mediated by Arcoxia (0663-093)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-04","conditions":"Pain","enrollment":237},{"nctId":"NCT00090181","phase":"PHASE4","title":"Study of MK0663 in Patients With Chronic Low Back Pain (0663-806)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-06","conditions":"Chronic Low Back Pain","enrollment":401},{"nctId":"NCT01462370","phase":"PHASE3","title":"Study to Assess the Safety and Efficacy of Etoricoxib Versus Ibuprofen in the Treatment of Dysmenorrhea (MK-0663-145 AM1)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2011-11","conditions":"Dysmenorrhea","enrollment":139},{"nctId":"NCT00788710","phase":"PHASE3","title":"A Study of MK0663/Etoricoxib for Post-Abdominal Hysterectomy Surgery Pain (0663-097)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2008-10","conditions":"Acute Pain Following a Total Abdominal Hysterectomy","enrollment":430},{"nctId":"NCT00945035","phase":"PHASE1","title":"Study of the Bioequivalence of the 20% and 30% Etoricoxib Tablet Formulations (0663-070)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2002-11","conditions":"Pain","enrollment":36},{"nctId":"NCT00694369","phase":"PHASE3","title":"A Study to Asses the Effect of MK0663 in the Treatment of Patients With Postoperative Dental Pain (0663-092)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2008-06","conditions":"Postoperative Dental Pain","enrollment":588},{"nctId":"NCT00757627","phase":"PHASE4","title":"Patient-Reported Effectiveness and Safety of Etoricoxib in Osteoarthritis (OA)(0663-113)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-12","conditions":"Pain","enrollment":500},{"nctId":"NCT00820027","phase":"PHASE3","title":"Study of MK-0663/Etoricoxib in Postorthopedic Knee Replacement Surgery Pain (MK-0663-098)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2008-12-15","conditions":"Pain, Postoperative","enrollment":776},{"nctId":"NCT01554163","phase":"PHASE3","title":"Safety and Efficacy of Etoricoxib 30 mg Versus Celecoxib 200 mg in Korean Participants With Osteoarthritis","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2012-03","conditions":"Osteoarthritis of the Knee","enrollment":239},{"nctId":"NCT01572675","phase":"","title":"A Study of the Patterns of Use of Etoricoxib in France (MK-0663-148)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2012-06","conditions":"Osteoarthritis","enrollment":547},{"nctId":"NCT00264147","phase":"PHASE2","title":"Rheumatoid Arthritis Dose Ranging Study (0663-086)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-01","conditions":"Rheumatoid Arthritis","enrollment":761},{"nctId":"NCT01067430","phase":"PHASE4","title":"Comparison of the Effect of Etoricoxib and Diclofenac on Early Morning Activity in Rheumatoid Arthritis (RA)","status":"WITHDRAWN","sponsor":"Northumbria Healthcare NHS Foundation Trust","startDate":"2010-04","conditions":"Rheumatoid Arthritis","enrollment":""},{"nctId":"NCT03117894","phase":"NA","title":"PECS-2 for Breast Surgery","status":"COMPLETED","sponsor":"Umeå University","startDate":"2017-05-23","conditions":"Breast Neoplasm Female, Regional Anesthesia, Anesthesia","enrollment":200},{"nctId":"NCT04830579","phase":"PHASE1","title":"Bioequivalence Study of Two Formulations of Etoricoxib Tablets 120 mg in Healthy Volunteers Under Fasting Conditions","status":"UNKNOWN","sponsor":"Pharmtechnology LLC","startDate":"2021-04-10","conditions":"Bioequivalence","enrollment":34},{"nctId":"NCT00746720","phase":"PHASE2","title":"Modulation of the Surgical Inflammatory Response by Etoricoxib","status":"TERMINATED","sponsor":"University of Erlangen-Nürnberg Medical School","startDate":"2006-05","conditions":"Pain, Osteoarthritis, Hip, Postoperative Pain","enrollment":23},{"nctId":"NCT03011905","phase":"PHASE3","title":"Rebound Pain After Operations for Distal Radius Fractures With a Volar Plate in Brachial Plexus Block","status":"COMPLETED","sponsor":"Oslo University Hospital","startDate":"2017-01","conditions":"Brachial Plexus Block, Pain, Postoperative","enrollment":53},{"nctId":"NCT04144101","phase":"PHASE4","title":"Etoricoxib vs Aceclofenac in the Treatment of Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Chung Shan Medical University","startDate":"2007-03-01","conditions":"Rheumatoid Arthritis","enrollment":40},{"nctId":"NCT03422575","phase":"NA","title":"Bioequivalence Study of 120 mg Etoricoxib Film-coated Tablets","status":"COMPLETED","sponsor":"Dexa Medica Group","startDate":"2015-12","conditions":"Healthy","enrollment":26},{"nctId":"NCT02954484","phase":"PHASE3","title":"Outcomes Of Perioperative Pregabalin On Total Knee Arthroplasty","status":"COMPLETED","sponsor":"National University Hospital, Singapore","startDate":"2015-04","conditions":"Pain, Postoperative","enrollment":116},{"nctId":"NCT01300780","phase":"NA","title":"Effect of an Anti-inflammatory on Tooth Sensitivity Caused by Bleaching","status":"COMPLETED","sponsor":"Eloisa Andrade de Paula","startDate":"2010-04","conditions":"Color Changes During Tooth Formation","enrollment":30},{"nctId":"NCT01269515","phase":"PHASE2","title":"Immunomodulating Therapy and Improved Vaccination Responses by Cox-2 Inhibitor in HIV-infected Patients","status":"COMPLETED","sponsor":"Dag Kvale","startDate":"2010-10","conditions":"HIV","enrollment":60},{"nctId":"NCT00427999","phase":"PHASE2","title":"Combined Antiinflammatory and Angiostatic Therapy in Patients With Hormone-refractory Prostate Cancer","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2007-02","conditions":"Prostate Cancer","enrollment":67},{"nctId":"NCT02884986","phase":"NA","title":"Analgesia in Inguinal Hernia Repair Using a Cyclooxygenase-2-specific Inhibitor","status":"COMPLETED","sponsor":"Bnai Zion Medical Center","startDate":"2015-01","conditions":"Adverse Anesthesia Outcome","enrollment":60},{"nctId":"NCT02750917","phase":"PHASE3","title":"Lornoxicam Versus Etoricoxib in Postoperative Pain After Total Knee Arthroplasty","status":"COMPLETED","sponsor":"Foisor Orthopedics Clinical Hospital","startDate":"2014-09","conditions":"Postoperative Pain","enrollment":120},{"nctId":"NCT02534610","phase":"NA","title":"Analgesic Benefit of Preoperative vs. Postoperative Etoricoxib in Total Knee Arthroplasty","status":"COMPLETED","sponsor":"Foisor Orthopedics Clinical Hospital","startDate":"2014-01","conditions":"Postoperative Pain","enrollment":165},{"nctId":"NCT01091675","phase":"PHASE3","title":"Assessment of the Response to Etoricoxib in Patients With Ankylosing Spondylitis and Inadequate Response to ≥2 NSAIDs","status":"COMPLETED","sponsor":"Spanish Foundation of Rheumatology","startDate":"2010-09","conditions":"Ankylosing Spondylitis","enrollment":58},{"nctId":"NCT02456363","phase":"PHASE2","title":"Anti-Tumor Necrosis Factor Therapy In Patients With Ankylosing Spondylitis","status":"UNKNOWN","sponsor":"Chung Shan Medical University","startDate":"2009-11","conditions":"Ankylosing Spondylitis","enrollment":300},{"nctId":"NCT01229774","phase":"PHASE3","title":"Use of Etoricoxib Compared to Diclofenac in the Perioperative Treatment of Patients After Total Hip Arthroplasty","status":"COMPLETED","sponsor":"University of Regensburg","startDate":"2011-02","conditions":"Coxarthrosis, Arthroplasties Hip Replacement, Perioperative Blood Loss","enrollment":100},{"nctId":"NCT02149758","phase":"PHASE4","title":"EFFECT OF SELECTIVE COX-2 INHIBITOR (ETORICOXIB) ALONG WITH SCALING AND ROOT PLANING (SRP) ON CLINICAL PARAMETERS AND SALIVARY LEVEL OF SUPEROXIDE DISMUTASE IN CHRONIC GENERALIZED PERIODONTITIS A DOUBLE-BLIND, PLACEBO-CONTROLLED, DOUBLE-MASKED RANDOMIZED CONTROLLED TRIAL (RCT).","status":"COMPLETED","sponsor":"Tatyasaheb Kore Dental College","startDate":"2013-01","conditions":"Cyclooxygenase Two Inhibitors, Etoricoxib, Periodontitis","enrollment":40},{"nctId":"NCT01259830","phase":"PHASE4","title":"Effectiveness of Etoricoxib as an Additive Analgesic to Epidural Analgesia in Colon or Rectal Fast-track Surgery","status":"TERMINATED","sponsor":"Claudia Spies","startDate":"2011-03","conditions":"Post-operative Pain","enrollment":81},{"nctId":"NCT01022190","phase":"PHASE4","title":"Prevention of Heterotopic Ossification With Arcoxia After Total Hip Replacement","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2009-12","conditions":"Ossification, Heterotopic","enrollment":42},{"nctId":"NCT00954785","phase":"PHASE4","title":"Etoricoxib in Acute Ankle Ligament Sprains","status":"WITHDRAWN","sponsor":"University of Cape Town","startDate":"2009-11","conditions":"Sprain","enrollment":""},{"nctId":"NCT01002690","phase":"NA","title":"COX-2 Inhibition in Allergic Asthma","status":"COMPLETED","sponsor":"Barbro Dahlen","startDate":"2009-10","conditions":"Asthma","enrollment":16},{"nctId":"NCT01088256","phase":"PHASE2","title":"Efficacy of Etoricoxib on Peripheral Hyperalgesia","status":"TERMINATED","sponsor":"Ruhr University of Bochum","startDate":"2011-02","conditions":"Causalgia, Polyneuropathy, Postherpetic Neuralgia","enrollment":9},{"nctId":"NCT00755521","phase":"PHASE4","title":"Study Assessing the Efficacy of Etoricoxib in Female Patients With Fibromyalgia","status":"UNKNOWN","sponsor":"Meir Medical Center","startDate":"2008-09","conditions":"Fibromyalgia","enrollment":80},{"nctId":"NCT01614301","phase":"PHASE1, PHASE2","title":"Phase I and Consecutive Phase II, Two-arm, Randomized Multi-center Trial in Patients With Advanced Melanoma","status":"UNKNOWN","sponsor":"University of Regensburg","startDate":"2012-05","conditions":"Advanced Melanoma","enrollment":136},{"nctId":"NCT00927004","phase":"PHASE4","title":"Efficacy of Etoricoxib 60 mg in Modifying Pain Hypersensitivity in People With Knee Osteoarthritis","status":"COMPLETED","sponsor":"Curtin University","startDate":"2010-08","conditions":"Osteoarthritis, Pain","enrollment":80},{"nctId":"NCT01361789","phase":"PHASE4","title":"COX-2 Inhibitor Versus Glucocorticoid Versus Both Combined","status":"COMPLETED","sponsor":"Asker & Baerum Hospital","startDate":"2004-01","conditions":"Rupture of Anterior Cruciate Ligament","enrollment":93},{"nctId":"NCT01264237","phase":"PHASE4","title":"Evaluation of the Efficacy, Tolerability and Safety of Etoricoxib (Arcoxia) in Patients With Neuropathic Pain","status":"UNKNOWN","sponsor":"Analgesic Solutions","startDate":"2011-03","conditions":"Postherpetic Neuralgia, Neuralgia","enrollment":120},{"nctId":"NCT01148303","phase":"PHASE4","title":"Trial of Etoricoxib (Arcoxia) Taken Prophylactically to Prevent Ramadan Headache","status":"COMPLETED","sponsor":"Hartford Hospital","startDate":"2010-07","conditions":"Headache, Fasting, Fasting Headache","enrollment":220},{"nctId":"NCT00554346","phase":"PHASE4","title":"A Randomized, Double Blind, Placebo-controlled Study to Assess the the Preemptive Benefit of Etoricoxib in Patients Receiving Anterior Cruciate Ligament Reconstruction","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2008-05","conditions":"Post-operational Pain","enrollment":64},{"nctId":"NCT00733421","phase":"PHASE4","title":"The Effect of Anti-inflammatory Analgesics on Pain Following Hallux Valgus Surgery","status":"COMPLETED","sponsor":"Karolinska Institutet","startDate":"2008-10","conditions":"Postoperative Pain","enrollment":100},{"nctId":"NCT00440739","phase":"PHASE4","title":"Etoricoxib With Flavoxate for Reducing Morphine Requirement After Transurethral Prostatectomy (TURP)","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2005-09","conditions":"Pain","enrollment":128},{"nctId":"NCT00565682","phase":"PHASE4","title":"Pain Post Abdominal Laparoscopy Prevention With Arcoxia","status":"COMPLETED","sponsor":"Hospital Vozandez","startDate":"2006-04","conditions":"Laparoscopic Surgery for Appendicitis, Laparoscopic Surgery for Cholecystitis, Laparoscopic Surgery for Ovarian Cysts","enrollment":60},{"nctId":"NCT00529594","phase":"NA","title":"Analgesic Effect of Etoricoxib (ARCOXIA®) 120MG During Retinal Laser Photocoagulation","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2006-08","conditions":"Proliferative Diabetic Retinopathy","enrollment":44}],"_emaApprovals":[],"_faersSignals":[{"count":2,"reaction":"HEPATITIS"},{"count":1,"reaction":"ANAEMIA"},{"count":1,"reaction":"DEPRESSED MOOD"},{"count":1,"reaction":"DIZZINESS"},{"count":1,"reaction":"FATIGUE"},{"count":1,"reaction":"HEPATIC NECROSIS"},{"count":1,"reaction":"LEUKOPENIA"},{"count":1,"reaction":"SUICIDAL IDEATION"}],"_approvalHistory":[],"publicationCount":18,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Etoricoxib, Arcoxia","Arcoxia"],"phase":"marketed","status":"active","brandName":"Etoricoxib (Arcoxia)","genericName":"Etoricoxib (Arcoxia)","companyName":"Radboud University Medical Center","companyId":"radboud-university-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Etoricoxib, also known as Arcoxia, is a small molecule that inhibits the cyclooxygenase-2 enzyme, specifically targeting prostaglandin G/H synthase 2. It has been studied for various conditions, including postoperative pain, rheumatoid arthritis, ankylosing spondylitis, and pain, among others.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}